MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.680
+0.020 (1.20%)
Nov 4, 2024, 4:00 PM EST - Market closed
MediciNova Employees
MediciNova had 13 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$76,923
Profits / Employee
-$628,070
Market Cap
82.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Coherus BioSciences | 306 |
InterCure | 270 |
DBV Technologies | 105 |
IO Biotech | 68 |
Aerovate Therapeutics | 51 |
Ikena Oncology | 43 |
Ovid Therapeutics | 40 |
Renovaro | 25 |
MNOV News
- 12 days ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire
- 5 weeks ago - MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 2 months ago - MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - GlobeNewsWire
- 2 months ago - MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting - GlobeNewsWire
- 2 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition - GlobeNewsWire
- 4 months ago - MediciNova Chief Business Officer David H. Crean, Ph.D. - GlobeNewsWire
- 5 months ago - MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer - GlobeNewsWire
- 5 months ago - MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 - GlobeNewsWire